In vitro study demonstrates that p160 MBP represses PGC-1α activity in myoblasts, suggesting a molecular mechanism for p38 MAPK-dependent metabolic control.
The transcriptional coactivator PPAR gamma coactivator 1 α (PGC-1α) is a key regulator of metabolic processes such as mitochondrial biogenesis and respiration in muscle and gluconeogenesis in liver. Reduced levels of PGC-1α in humans have been associated with type II diabetes. PGC-1α contains a negative regulatory domain that attenuates its transcriptional activity. This negative regulation is removed by phosphorylation of PGC-1α by p38 MAPK, an important kinase downstream of cytokine signaling in muscle and β-adrenergic signaling in brown fat. We describe here the identification of p160 myb binding protein (p160 MBP ) as a repressor of PGC-1α. The binding and repression of PGC-1α by p160 MBP is disrupted by p38 MAPK phosphorylation of PGC-1α. Adenoviral expression of p160 MBP in myoblasts strongly reduces PGC-1α's ability to stimulate mitochondrial respiration and the expression of the genes of the electron transport system. This repression does not require removal of PGC-1α from chromatin, suggesting that p160 MBP is or recruits a direct transcriptional suppressor. Overall, these data indicate that p160 MBP is a powerful negative regulator of PGC-1α function and provide a molecular mechanism for the activation of PGC-1α by p38 MAPK. The discovery of p160 MBP as a PGC-1α regulator has important implications for the understanding of energy balance and diabetes.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: